Syndax Pharmaceuticals (SNDX) PT Lowered to $29 at B.Riley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
March 4, 2025 5:46 AM ESTBTIG analyst Justin Zelin reiterated a Buy rating and $43.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).
The analyst comments "SNDX reported 4Q24 earnings, detailing a solid $7.7M in net revenue for REVUFORJ (cons $2M) in the first 5 weeks of launch. Mgmt noted traction... More
Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Goldman Sachs
March 4, 2025 4:55 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst comments "Syndax Pharmaceuticals (SNDX) reported 4Q24 results which featured the company's first reporting of commercial sales for Revuforj since the November 2024 approval. Revenues of $7.7mn (inclusive... More
